Stock LEGN LEGEND BIOTECH CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

News Legend Biotech Corporation

Equities

LEGN

US52490G1022

Real-time Estimate Cboe BZX
Other stock markets
 11:30:19 2024-04-26 am EDT 		5-day change 1st Jan Change
44.51 USD +0.20% Intraday chart for Legend Biotech Corporation -3.72% -26.09%
Apr. 23 Genscript Biotech Unit Gets Approval for Blood Cancer Drug by European Commission MT
Apr. 22 Legend Biotech's Carvykti Gets European Commission Approval for Treatment of Blood Cancer MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Genscript Biotech Unit Gets Approval for Blood Cancer Drug by European Commission
MT
Legend Biotech's Carvykti Gets European Commission Approval for Treatment of Blood Cancer
MT
CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
BU
Legend Biotech Corporation's CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
CI
US FDA mandates label updates on CAR-T cancer therapies
RE
Scotiabank Upgrades Legend Biotech to Sector Outperform From Sector Perform, Price Target is $65
MT
Genscript Biotech's Unit Logs $157 Million in Q1 Sales of Blood Cancer Drug
MT
Legend Biotech : Announces Preliminary Sales for CARVYKTI® for the Quarter Ended March 31, 2024 - Form 6-K
PU
Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results
BU
Genscript Biotech Unit's Refractory Multiple Myeloma Drug Gets FDA Approval
MT
Innovative personalised immunotherapy approved for multiple myeloma
AQ
Sector Update: Health Care Stocks Flat to Higher Premarket Monday
MT
Johnson & Johnson, Legend Biotech's Carvykti Receives FDA Approval to Treat Relapsed, Refractory Multiple Myeloma
MT
U.S. FDA approves expanded use of J&J's cancer cell therapy
RE
Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
BU
Legend Biotech Corporation's CARVYKTI Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
CI
US FDA allows expanded use of Bristol Myers' cell therapy for blood cancer
RE
U.S. FDA allows expanded use of Bristol Myers' cell therapy
RE
Cantor Fitzgerald Initiates Legend Biotech With Overweight Rating
MT
Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance Report
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LEGN Stock
  4. News Legend Biotech Corporation